E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene |
|
E.1.1.1 | Medical condition in easily understood language |
Progressive reduction in vision, starting with night blindness and progressing to visual field constriction, caused by mutations on Chromosome X (RPGR gene). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10038914 |
E.1.2 | Term | Retinitis pigmentosa |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary research objective is to assess the longer term safety of AAV2/5-hRKp.RPGR administered to participants in the RPGR trial, measured by the presence or absence of adverse events, the assessment of visual acuity, and loss of light perception. |
|
E.2.2 | Secondary objectives of the trial |
The secondary research objective is to explore the longer-term efficacy of AAV2/5-hRKp.RPGR in improving visual and retinal function, and quality of life, and protecting against sight impairment from retinal degeneration. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion in the study will be limited to individuals who meet the following criteria:
• Are able to give informed consent or assent, with or without the guidance of their parent/guardian where appropriate
• Received AAV2/5-hRKp.RPGR by sub retinal administration in the prior open-label, Phase I/II, dose escalation study (EudraCT 2016-003967-21)
• Are willing to adhere to the protocol and long-term follow-up |
|
E.4 | Principal exclusion criteria |
Individuals will be excluded if they are unwilling or unable to meet with the requirements of the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome is longer term safety of subretinal administration of AAV2/5-hRKp.RPGR (administered in the XLRP RPGR clinical trial). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At 24, 36, 48 and 60 months after AAV2/5-hRKp.RPGR administration |
|
E.5.2 | Secondary end point(s) |
The secondary outcomes are measures of the longer-term efficacy of the original intervention, which will be performed on an individual participant basis and will be descriptive in nature.
Efficacy will be assessed at several time points between 18 months and 5 years after the intervention:
1) Slowing or halting of progressive deterioration in retinal structure or visual function that is greater than the test-retest variation for that test and is sustained for at least two consecutive assessments. Slowing or halting of progression over time may be facilitated by comparing identical structural and functional assessments acquired prior to intervention/injection to better determine rate of change over time in this slowly progressive disease.
2) Any improvement in visual function from baseline that is greater than the test-retest variation for that test and is sustained for at least two consecutive assessments.
3) Any improvement in retinal function from pre-intervention that is greater than test-retest variation and measurable by electrophysiology (pattern ERG, multifocal ERG or full-field ERG).
4) Quality of life will be measured by the Impact of Visual Impairment (IVI) questionnaire and the EQ5D-5L and EQ-5D-Y |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At 24, 36, 48 and 60 months after AAV2/5-hRKp.RPGR administration |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Long Term Follow Up Trial |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 30 |